Jefferies Upgrades Relay Therapeutics to Buy, Raises Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Akash Tewari has upgraded Relay Therapeutics (NASDAQ:RLAY) from Hold to Buy, increasing the price target from $10.6 to $16.
September 10, 2024 | 12:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies has upgraded Relay Therapeutics from Hold to Buy, with a new price target of $16, indicating a positive outlook for the stock.
The upgrade from Hold to Buy by Jefferies, along with a significant increase in the price target, suggests a positive short-term impact on Relay Therapeutics' stock price. This indicates increased confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100